|
WO2020232379A1
|
|
Oil-soluble drug containing compositions and methods of use thereof
|
|
EP3793558A1
|
|
Formulations and methods for the prevention of opioid overdose
|
|
WO2019157099A1
|
|
Intranasal epinephrine formulations and methods for the treatment of disease
|
|
KR20200121818A
|
|
Intranasal epinephrine preparations and methods of treating diseases
|
|
US2018169247A1
|
|
Compositions for drug administration
|
|
AU2017360910A1
|
|
Compositions and methods for the treatment of opioid overdose
|
|
US2018000942A1
|
|
Compositions for drug administration
|
|
WO2015095389A1
|
|
Compositions for drug administration
|
|
CN103347532A
|
|
Orally bioavailable peptide drug compositions and methods thereof
|
|
CN103189068A
|
|
Compositions for drug administration
|
|
US2011046058A1
|
|
Compositions for enteral absorption and sustained action of leptin-related peptides useful in the treatment of obesity and leptin-modulated disease
|
|
US2010203014A1
|
|
Zwitterionic buffered acidic peptide and protein formulations
|
|
US2009326193A1
|
|
Stabilizing alkylglycoside compositions and methods thereof
|
|
WO2009029543A1
|
|
Controlled release formulations
|
|
US2008268032A1
|
|
Stabilizing alkylglycoside compositions and methods thereof
|
|
EP2158898A1
|
|
Stabilizing alkylglycoside compositions and method thereof
|
|
US2006046969A1
|
|
Antibacterial compositions for drug administration
|
|
US2006046962A1
|
|
Absorption enhancers for drug administration
|
